8-K: Coya Therapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Coya Therapeutics announces its FY2024 financial results, highlighting progress in clinical trials and pipeline expansion, with a focus on neurodegenerative diseases.

Summary

• Coya Therapeutics announced its financial results for the year ended December 31, 2024, along with a corporate update.
• The company reported significant improvements in inflammatory blood markers from a Phase 2 study of low-dose interleukin-2 (LD IL-2) in Alzheimer's disease (AD).
• Five of eight patients have been enrolled in an investigator-initiated academic study of LD IL-2 + CTLA4-Ig combination in patients with Frontotemporal Dementia (FTD).
• Coya aligned with the FDA on non-clinical data for a Phase 2b trial of COYA-302 in Amyotrophic Lateral Sclerosis (ALS).
• The company expanded its pipeline with COYA 303 and a combination of COYA 301 with a GLP-1 Receptor Agonist for inflammatory diseases.
• Coya raised $10.0 million in a private placement and received a $5.0 million strategic investment from the Alzheimer's Drug Discovery Foundation (ADDF).
• They also received $3.85 million from Dr. Reddy's Laboratories for funding the first Phase 2 clinical trial of COYA 302 in ALS.
• Coya had cash and cash equivalents of $38.3 million as of December 31, 2024.
• Research and development (R&D) expenses were $11.9 million for the year ended December 31, 2024, compared to $5.5 million for the year ended December 31, 2023.
• Net loss was $14.9 million for the year ended December 31, 2024, compared to a net loss of $8.0 million for the year ended December 31, 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported increased losses and expenses, it also highlighted progress in clinical trials, pipeline expansion, and secured funding. The management's comments are optimistic about future prospects.

Positives

• Coya Therapeutics has a strong cash position of $38.3 million.
• The company is making significant progress on ongoing programs in neurodegenerative diseases.
• Coya is on track to initiate a randomized, double-blind controlled Phase 2b trial in patients with ALS.
• The company has expanded its pipeline with COYA 303 and a combination of COYA 301 with a GLP-1 Receptor Agonist for inflammatory diseases.
• Coya received $5.0 million from the Alzheimer's Drug Discovery Foundation (ADDF) to support the development of COYA 302 for Frontotemporal Dementia (FTD).

Negatives

• Coya Therapeutics reported a net loss of $14.9 million for the year ended December 31, 2024, compared to a net loss of $8.0 million for the year ended December 31, 2023.
• Research and development (R&D) expenses increased to $11.9 million for the year ended December 31, 2024, compared to $5.5 million for the year ended December 31, 2023.
• General and administrative expenses increased to $8.9 million for the year ended December 31, 2024, from $7.8 million for the year ended December 31, 2023.

Risks

• The company's forward-looking statements are subject to known and unknown risks, uncertainties, and assumptions.
• These risks include the success, cost, and timing of product candidate development activities and clinical trials.
• The company's ability to obtain funding for operations, development, and commercialization of product candidates is a risk.
• The timing of and ability to obtain and maintain regulatory approvals is uncertain.
• The rate and degree of market acceptance and clinical utility of product candidates are not guaranteed.

Future Outlook

Coya Therapeutics anticipates important milestones in 2025, including initiating the Phase 2b trial of COYA 302 in ALS patients and submitting an IND for a Phase 2b study of COYA 302 in FTD patients.

Management Comments

• Coya CEO Arun Swaminathan, Ph.D. commented, 'We remain encouraged by the progress we made in 2024 and are well positioned for continued success in 2025.'
• Swaminathan stated that the company continues to expand its pipeline while making significant progress on ongoing programs in neurodegenerative diseases.
• Coya CMO, Dr. Fred Grossman said, 'As we have indicated in the past, we expect 2025 to hold important milestones for the Company, including initiating the phase 2b trial of COYA 302, which is the combination of LD-IL2 and CTLA 4 IG, in ALS patients.'

Industry Context

Coya Therapeutics is focused on developing treatments for neurodegenerative diseases by targeting neuroinflammation, a key factor in disease progression. Their approach to potential combination therapies differentiates them from other companies in the field.

Comparison to Industry Standards

• Coya's focus on Treg-enhancing biologics aligns with the growing interest in immunomodulatory approaches for neurodegenerative diseases, similar to strategies employed by companies like Annexon Biosciences and Alector.
• The company's collaboration with Dr. Reddy's Laboratories mirrors partnerships seen in the biotech industry to accelerate clinical development and share financial risk, comparable to deals between larger pharmaceutical companies and smaller biotechs like Biohaven and Bristol Myers Squibb.
• Coya's cash position of $38.3 million is relatively modest compared to larger, more established biotech companies, but it is sufficient to fund near-term clinical trials and pipeline expansion, similar to the funding strategies of other clinical-stage biotechs like Denali Therapeutics and Voyager Therapeutics.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and progress in clinical trials.
• Employees are affected by the company's growth and expansion plans.
• Patients with neurodegenerative diseases may benefit from the development of new treatments.
• Suppliers and creditors are impacted by the company's financial stability and ability to meet obligations.

Next Steps

• Submission of additional nonclinical data to the FDA to support the initiation of the Phase 2 trial in patients with ALS in Q2 2025.
• Publication of COYA-303 combination mechanistic data in Q2 2025.
• Publication of data documenting the role of inflammation in Parkinson's Disease in Q2 2025.
• Publication of ALS Biomarker data in Q2 2025.
• Release of top-line clinical data for an investigator-initiated trial combining LD IL-2 + CTLA4-Ig in patients with FTD in 2H 2025.
• Filing of IND for the COYA-302 Phase 2 trial in patients with FTD in 2H 2025.

Key Dates